stockrowNeurocrine Biosciences, Inc.
NBIX Healthcare Drug Manufacturers Specialty & Generic
Neurocrine Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.9 billion, up 21.4% from fiscal 2024.
- Revenue
- +41.2%
- EPS
- −3.67%
- Free cash flow
- +79.0%
Quarter to September 2026, against a year earlier
Follow NBIX
Alert me
Neurocrine Biosciences, Inc. (NBIX) Revenue
Neurocrine Biosciences, Inc.'s revenue for fiscal 2025 was $2.9B, up 21.4% from $2.4B in fiscal 2024. Over the twelve months to 30 September 2026 it was $3.7B. Over the past ten years it has ranged from $15.0M (fiscal 2016) to $2.9B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 9 consecutive fiscal years. Neurocrine Biosciences, Inc. ranks 9th of 74 Drug Manufacturers Specialty & Generic companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $2.9B | 21.45% |
| FY2024 | $2.4B | 24.81% |
| FY2023 | $1.9B | 26.76% |
| FY2022 | $1.5B | 31.34% |
| FY2021 | $1.1B | 8.38% |
| FY2020 | $1.0B | 32.71% |
| FY2019 | $788.1M | 74.67% |
| FY2018 | $451.2M | 179.16% |
| FY2017 | $161.6M | 977.51% |
| FY2016 | $15.0M | (24.12%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.1B | 17.07% |
| Jun 2026 | $959.0M | 17.74% |
| Mar 2026 | $814.5M | 1.12% |
| Dec 2025 | $805.5M | 1.33% |
| 36 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| HLN Haleon PLC Sponsored ADR compare | $18.1B |
| VTRS Viatris Inc. compare | $14.7B |
| ZTS Zoetis Inc. compare | $9.5B |
| ELAN Elanco Animal Health Incorporated compare | $5.0B |
| NBIX Neurocrine Biosciences, Inc. | $3.7B |
| RDY Dr. Reddy's Laboratories Ltd compare | $3.3B |
| UTHR United Therapeutics Corporation compare | $3.2B |
| ALKS Alkermes plc compare | $1.8B |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $946.0M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on NBIX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement